

# C Robert Horsburgh

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/879816/publications.pdf>

Version: 2024-02-01

139  
papers

10,097  
citations

66343

42  
h-index

36028

97  
g-index

143  
all docs

143  
docs citations

143  
times ranked

8715  
citing authors

#	ARTICLE	IF	CITATIONS
1	Contribution of Reinfection to Annual Rate of Tuberculosis Infection (ARI) and Incidence of Tuberculosis Disease. <i>Clinical Infectious Diseases</i> , 2023, 76, e965-e972.	5.8	4
2	Trends, Mechanisms, and Racial/Ethnic Differences of Tuberculosis Incidence in the US-Born Population Aged 50 Years or Older in the United States. <i>Clinical Infectious Diseases</i> , 2022, 74, 1594-1603.	5.8	9
3	Accuracy of Timika X-ray scoring system to predict the treatment outcomes among tuberculosis patients in India. <i>Indian Journal of Tuberculosis</i> , 2022, 69, 476-481.	0.7	2
4	“People listen more to what actors say”: A qualitative study of tuberculosis-related knowledge, behaviours, stigma, and potential interventions in Puducherry, India. <i>Global Public Health</i> , 2022, 17, 2898-2910.	2.0	4
5	What Can Genetic Relatedness Tell Us About Risk Factors for Tuberculosis Transmission?. <i>Epidemiology</i> , 2022, 33, 55-64.	2.7	1
6	Attrition from HIV care among youth initiating ART in youth-only clinics compared with general primary healthcare clinics in Khayelitsha, South Africa: a matched propensity score analysis. <i>Journal of the International AIDS Society</i> , 2022, 25, e25854.	3.0	4
7	Treatments of Multidrug-Resistant Tuberculosis: Light at the End of the Tunnel. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 1142-1144.	5.6	10
8	Testing and treatment for latent tuberculosis infection in people living with HIV and substance dependence: a prospective cohort study. <i>BMJ Open</i> , 2022, 12, e058751.	1.9	4
9	Missed Tuberculosis Diagnoses: Analysis of Pediatric Autopsy Data From General Hospitals in Lviv, Ukraine. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2022, 11, 300-302.	1.3	2
10	Incidence and Mortality of Extrapulmonary Tuberculosis in Ukraine: Analysis of National Surveillance Data. <i>Clinical Infectious Diseases</i> , 2022, 75, 604-612.	5.8	6
11	Cost-effectiveness of a Novel Lipoarabinomannan Test for Tuberculosis in Patients With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2021, 73, e2077-e2085.	5.8	10
12	Comparing tuberculosis gene signatures in malnourished individuals using the TBSignatureProfiler. <i>BMC Infectious Diseases</i> , 2021, 21, 106.	2.9	10
13	Estimation of the generation interval using pairwise relative transmission probabilities. <i>Biostatistics</i> , 2021, , .	1.5	1
14	Alcohol and Tobacco Use in a Tuberculosis Treatment Cohort during South Africa’s COVID-19 Sales Bans: A Case Series. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 5449.	2.6	10
15	Directly Observed Therapy to Measure Adherence to Tuberculosis Medication in Observational Research: Protocol for a Prospective Cohort Study. <i>JMIR Research Protocols</i> , 2021, 10, e24510.	1.0	0
16	Antibiotics and fecundability among female pregnancy planners: a prospective cohort study. <i>Human Reproduction</i> , 2021, 36, 2761-2768.	0.9	5
17	Severe undernutrition in children affects tuberculin skin test performance in Southern India. <i>PLoS ONE</i> , 2021, 16, e0250304.	2.5	2
18	Comparison of profile and treatment outcomes between elderly and non-elderly tuberculosis patients in Puducherry and Tamil Nadu, South India. <i>PLoS ONE</i> , 2021, 16, e0256773.	2.5	17

#	ARTICLE	IF	CITATIONS
19	Self-reported Engagement in Care among U.S. Residents with Latent Tuberculosis Infection: 2011–2012. <i>Annals of the American Thoracic Society</i> , 2021, 18, 1669-1676.	3.2	5
20	Risk factors for death during treatment in pulmonary tuberculosis patients in South India: A cohort study. <i>Indian Journal of Tuberculosis</i> , 2021, 68, 32-39.	0.7	7
21	Tuberculosis—Learning the Impact of Nutrition (TB LION): protocol for an interventional study to decrease TB risk in household contacts. <i>BMC Infectious Diseases</i> , 2021, 21, 1058.	2.9	5
22	Prevalence and risk factors associated with latent tuberculosis infection among household contacts of smear positive pulmonary tuberculosis patients in South India. <i>Tropical Medicine and International Health</i> , 2021, 26, 1645-1651.	2.3	16
23	—Plus —a Change— Clinical Infectious Diseases, 2020, 70, 2119-2120.	5.8	1
24	Optimizing the Design of Latent Tuberculosis Treatment Trials: Insights from Mathematical Modeling. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 598-605.	5.6	7
25	Shortened Tuberculosis Treatment for People with HIV in South Africa. A Model-based Evaluation and Cost-effectiveness Analysis. <i>Annals of the American Thoracic Society</i> , 2020, 17, 202-211.	3.2	3
26	DAR-901 vaccine for the prevention of infection with <i>Mycobacterium tuberculosis</i> among BCG-immunized adolescents in Tanzania: A randomized controlled, double-blind phase 2b trial. <i>Vaccine</i> , 2020, 38, 7239-7245.	3.8	28
27	Evaluation of factors influencing <i>Mycobacterium tuberculosis</i> complex recovery and contamination rates in MGIT960. <i>Indian Journal of Tuberculosis</i> , 2020, 67, 466-471.	0.7	2
28	Household food insecurity among patients with pulmonary tuberculosis and its associated factors in South India: a cross-sectional analysis. <i>BMJ Open</i> , 2020, 10, e033798.	1.9	8
29	Increasing Drug Resistance Among Persons With Tuberculosis in Massachusetts, 2009–2018. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa300.	0.9	0
30	The risk of tuberculosis in children after close exposure: a systematic review and individual-participant meta-analysis. <i>Lancet, The</i> , 2020, 395, 973-984.	13.7	160
31	Challenging the management of drug-resistant tuberculosis — Authors' reply. <i>Lancet, The</i> , 2020, 395, 783-784.	13.7	1
32	Estimating the relative probability of direct transmission between infectious disease patients. <i>International Journal of Epidemiology</i> , 2020, 49, 764-775.	1.9	10
33	Guidelines for the treatment of latent tuberculosis infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. <i>American Journal of Transplantation</i> , 2020, 20, 1196-1206.	4.7	31
34	Reply to Swindells et al.: Trials of Tuberculosis-Preventive Therapy in People with HIV Infection. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 305-306.	5.6	0
35	Clinical manifestations and epidemiology of adolescent tuberculosis in Ukraine. <i>ERJ Open Research</i> , 2020, 6, 00308-2020.	2.6	9
36	Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. <i>MMWR Recommendations and Reports</i> , 2020, 69, 1-11.	61.1	262

#	ARTICLE	IF	CITATIONS
37	Predictors of Loss to Follow-Up among Men with Tuberculosis in Puducherry and Tamil Nadu, India. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 103, 1050-1056.	1.4	11
38	Interaction of nutritional status and diabetes on active and latent tuberculosis: a cross-sectional analysis. <i>BMC Infectious Diseases</i> , 2019, 19, 627.	2.9	21
39	Paediatric tuberculosis transmission outside the household: challenging historical paradigms to inform future public health strategies. <i>Lancet Respiratory Medicine</i> , 2019, 7, 544-552.	10.7	52
40	Switching to bedaquiline for treatment of rifampicin-resistant tuberculosis in South Africa: A retrospective cohort analysis. <i>PLoS ONE</i> , 2019, 14, e0223308.	2.5	5
41	Partitioning the risk of tuberculosis transmission in household contact studies. <i>PLoS ONE</i> , 2019, 14, e0223966.	2.5	11
42	One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. <i>New England Journal of Medicine</i> , 2019, 381, e23.	27.0	9
43	Management of drug-resistant tuberculosis. <i>Lancet</i> , 2019, 394, 953-966.	13.7	186
44	Cost-effectiveness of urine-based tuberculosis screening in hospitalised patients with HIV in Africa: a microsimulation modelling study. <i>The Lancet Global Health</i> , 2019, 7, e200-e208.	6.3	32
45	Detection, survival and infectious potential of <i>Mycobacterium tuberculosis</i> in the environment: a review of the evidence and epidemiological implications. <i>European Respiratory Journal</i> , 2019, 53, 1802302.	6.7	26
46	Effect of malnutrition on radiographic findings and mycobacterial burden in pulmonary tuberculosis. <i>PLoS ONE</i> , 2019, 14, e0214011.	2.5	33
47	Deriving the optimal limit of detection for an HCV point-of-care test for viraemic infection: Analysis of a global dataset. <i>Journal of Hepatology</i> , 2019, 71, 62-70.	3.7	17
48	Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, e93-e142.	5.6	282
49	Undernutrition and Tuberculosis: Public Health Implications. <i>Journal of Infectious Diseases</i> , 2019, 219, 1356-1363.	4.0	92
50	Pediatric Multidrug-resistant Tuberculosis in Kyiv City, Ukraine. <i>Journal of Epidemiology and Global Health</i> , 2019, 9, 56.	2.9	3
51	Nontuberculous Mycobacteria and Testing for Latent Tuberculosis Infection. <i>Clinical Infectious Diseases</i> , 2018, 67, 1308-1308.	5.8	1
52	Existing blood transcriptional classifiers accurately discriminate active tuberculosis from latent infection in individuals from south India. <i>Tuberculosis</i> , 2018, 109, 41-51.	1.9	51
53	Isoniazid Preventive Therapy for People With HIV Who Are Heavy Alcohol Drinkers in High TB-/HIV-Burden Countries: A Risk-Benefit Analysis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 405-412.	2.1	6
54	Cost-Effectiveness of One-Time Hepatitis C Screening Strategies Among Adolescents and Young Adults in Primary Care Settings. <i>Clinical Infectious Diseases</i> , 2018, 66, 376-384.	5.8	62

#	ARTICLE	IF	CITATIONS
55	Brief Report: Assessing the Association Between Changing NRTIs When Initiating Second-Line ART and Treatment Outcomes. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 413-416.	2.1	2
56	2570. HCV Screening Practices Among Adolescents and Young Adults in a National Sample of Federally Qualified Health Centers in the United States. <i>Open Forum Infectious Diseases</i> , 2018, 5, S74-S74.	0.9	1
57	Effect of Antiretroviral Therapy on Treatment Outcomes in a Prospective Study of Extensively Drug-Resistant Tuberculosis (XDR-TB) HIV Coinfection Treatment in KwaZulu-Natal, South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, 474-480.	2.1	14
58	In reply. <i>International Journal of Tuberculosis and Lung Disease</i> , 2018, 22, 968-968.	1.2	0
59	Impact of Choice of Test for Latent Tuberculosis Infection on Treatment Acceptance and Completion. <i>Microbiology Insights</i> , 2018, 11, 117863611881131.	2.0	2
60	Impact of alcohol consumption on tuberculosis treatment outcomes: a prospective longitudinal cohort study protocol. <i>BMC Infectious Diseases</i> , 2018, 18, 488.	2.9	30
61	Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	18
62	MDR-TB in children: back to the basics. <i>International Journal of Tuberculosis and Lung Disease</i> , 2018, 22, 1-2.	1.2	2
63	Has compassionate use ever sunk a drug?. <i>International Journal of Tuberculosis and Lung Disease</i> , 2018, 22, 119-120.	1.2	1
64	The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. <i>Lancet Respiratory Medicine</i> , 2017, 5, 291-360.	10.7	459
65	Cost-effectiveness of Testing and Treatment for Latent Tuberculosis Infection in Residents Born Outside the United States With and Without Medical Comorbidities in a Simulation Model. <i>JAMA Internal Medicine</i> , 2017, 177, 1755.	5.1	53
66	Predictors of delayed care seeking for tuberculosis in southern India: an observational study. <i>BMC Infectious Diseases</i> , 2017, 17, 567.	2.9	27
67	Cost Effectiveness and Cost Containment in the Era of Interferon-Free Therapies to Treat Hepatitis C Virus Genotype 1. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofw266.	0.9	14
68	An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial. <i>Trials</i> , 2017, 18, 563.	1.6	17
69	Comorbidities in pulmonary tuberculosis cases in Puducherry and Tamil Nadu, India: Opportunities for intervention. <i>PLoS ONE</i> , 2017, 12, e0183195.	2.5	31
70	The Cost-Effectiveness of Hepatitis C Screening Strategies Among Adolescents and Young Adults in Primary Care Settings. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
71	The complexity of diagnosing latent tuberculosis infection in older adults in long-term care facilities. <i>International Journal of Infectious Diseases</i> , 2016, 44, 37-43.	3.3	11
72	Isolation of <i>Mycobacterium avium</i> from Potable Water in Homes and Institutions of Patients with HIV Infection in Finland and the United States. <i>BioMed Research International</i> , 2015, 2015, 1-3.	1.9	4

#	ARTICLE	IF	CITATIONS
73	CD4 Recovery on Antiretroviral Therapy Is Associated With Decreased Progression to Liver Disease Among Hepatitis C Virus-Infected Injecting Drug Users. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv019.	0.9	10
74	Management of latent <i>Mycobacterium tuberculosis</i> infection: WHO guidelines for low tuberculosis burden countries. <i>European Respiratory Journal</i> , 2015, 46, 1563-1576.	6.7	475
75	Overestimation of Coprevalent and Underestimation of Incident Tuberculosis in Close Contacts. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, 486-487.	5.6	1
76	A Century of Tuberculosis Epidemiology in the Northern and Southern Hemisphere: The Differential Impact of Control Interventions. <i>PLoS ONE</i> , 2015, 10, e0135179.	2.5	38
77	<i>Mycobacterium avium</i> Complex. , 2015, , 2832-2843.e3.		5
78	Principles for designing future regimens for multidrug-resistant tuberculosis. <i>Bulletin of the World Health Organization</i> , 2014, 92, 68-74.	3.3	60
79	Tuberculosis. <i>European Respiratory Review</i> , 2014, 23, 36-39.	7.1	5
80	Relationship Between Hepatitis C Clinical Testing Site and Linkage to Care. <i>Open Forum Infectious Diseases</i> , 2014, 1, ofu009.	0.9	17
81	Estimated Rate of Reactivation of Latent Tuberculosis Infection in the United States, Overall and by Population Subgroup. <i>American Journal of Epidemiology</i> , 2014, 179, 216-225.	3.4	172
82	Editorial Commentary: Treatment for Multidrug-Resistant Tuberculosis: It's Worse Than We Thought!. <i>Clinical Infectious Diseases</i> , 2014, 59, 1064-1065.	5.8	9
83	Randomized clinical trials to identify optimal antibiotic treatment duration. <i>Trials</i> , 2013, 14, 88.	1.6	14
84	Compassionate use of and expanded access to new drugs for drug-resistant tuberculosis [Review article]. <i>International Journal of Tuberculosis and Lung Disease</i> , 2013, 17, 146-152.	1.2	26
85	Increased mortality associated with treated active tuberculosis in HIV-infected adults in Tanzania. <i>Tuberculosis</i> , 2013, 93, 461-466.	1.9	6
86	Predictors of Active Injection Drug Use in a Cohort of Patients Infected With Hepatitis C Virus. <i>American Journal of Public Health</i> , 2013, 103, 105-111.	2.7	9
87	Treatment Outcomes for Extensively Drug-Resistant Tuberculosis and HIV Co-infection. <i>Emerging Infectious Diseases</i> , 2013, 19, 416-424.	4.3	100
88	Prevention of Tuberculosis in Older Adults in the United States: Obstacles and Opportunities. <i>Clinical Infectious Diseases</i> , 2013, 56, 1240-1247.	5.8	58
89	Risk of Progression to Active Tuberculosis Following Reinfection With <i>Mycobacterium tuberculosis</i> . <i>Clinical Infectious Diseases</i> , 2012, 54, 784-791.	5.8	303
90	Latent Tuberculosis Infection in the United States. <i>New England Journal of Medicine</i> , 2011, 364, 1441-1448.	27.0	277

#	ARTICLE	IF	CITATIONS
91	Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection. <i>New England Journal of Medicine</i> , 2011, 365, 2155-2166.	27.0	769
92	Extensively Drug-Resistant Tuberculosis in Women, KwaZulu-Natal, South Africa. <i>Emerging Infectious Diseases</i> , 2011, 17, 1942-1945.	4.3	16
93	Polyantigenic Interferon- $\gamma$ Responses Are Associated with Protection from TB among HIV-Infected Adults with Childhood BCG Immunization. <i>PLoS ONE</i> , 2011, 6, e22074.	2.5	14
94	Evaluation of exposure-specific risks from two independent samples: A simulation study. <i>BMC Medical Research Methodology</i> , 2011, 11, 1.	3.1	225
95	Priorities for Screening and Treatment of Latent Tuberculosis Infection in the United States. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 184, 590-601.	5.6	139
96	Diabetes, Glycemic Control, and Risk of Tuberculosis. <i>Diabetes Care</i> , 2011, 34, 2530-2535.	8.6	70
97	Risk Factors for Nonadherence with Pap Testing in HIV-Infected Women. <i>Journal of Women's Health</i> , 2011, 20, 1635-1643.	3.3	30
98	Interferon $\gamma$ Responses to Mycobacterial Antigens Protect against Subsequent HIV-Associated Tuberculosis. <i>Journal of Infectious Diseases</i> , 2010, 202, 1265-1272.	4.0	29
99	Latent TB Infection Treatment Acceptance and Completion in the United States and Canada. <i>Chest</i> , 2010, 137, 401-409.	0.8	197
100	Revisiting Rates of Reactivation Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 420-425.	5.6	124
101	Encouraging News for Multidrug-resistant Tuberculosis Treatment. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 1337-1338.	5.6	7
102	Immunogenicity of a protective whole cell mycobacterial vaccine in HIV-infected adults: A phase III study in Tanzania. <i>Vaccine</i> , 2010, 28, 7652-7658.	3.8	38
103	Noninvasive Markers of Liver Fibrosis Are Highly Predictive of Liver-Related Death in a Cohort of HCV-Infected Individuals With and Without HIV Infection. <i>American Journal of Gastroenterology</i> , 2010, 105, 1346-1353.	0.4	134
104	The associations of binge alcohol use with HIV/STI risk and diagnosis among heterosexual African American men. <i>Drug and Alcohol Dependence</i> , 2009, 101, 101-106.	3.2	57
105	Basis for treatment of tuberculosis among HIV-infected patients in Tanzania: the role of chest x-ray and sputum culture. <i>BMC Infectious Diseases</i> , 2008, 8, 32.	2.9	27
106	Predictors of Treatment for Hepatitis C Virus (HCV) Infection in Drug Users. <i>Substance Abuse</i> , 2008, 29, 5-15.	2.3	2
107	Recent drug use, homelessness and increased short-term mortality in HIV-infected persons with alcohol problems. <i>Aids</i> , 2008, 22, 415-420.	2.2	43
108	Primary Transmission of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis among HIV-Infected Persons: What Does the Future Hold in Store?. <i>Journal of Infectious Diseases</i> , 2008, 198, 1577-1578.	4.0	7



#	ARTICLE	IF	CITATIONS
109	Use of a Population-Based Survey to Describe the Health of Boston Public Housing Residents. <i>American Journal of Public Health</i> , 2008, 98, 85-91.	2.7	126
110	History of Incarceration and Gang Involvement Are Associated With Recent Sexually Transmitted Disease/HIV Diagnosis in African American Men. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2008, 47, 131-134.	2.1	17
111	Baseline Mycobacterial Immune Responses in HIV-Infected Adults Primed with bacille Calmette-Guérin during Childhood and Entering a Tuberculosis Booster Vaccine Trial. <i>Journal of Infectious Diseases</i> , 2007, 195, 118-123.	4.0	22
112	Effect of Exposure to Injection Drugs or Alcohol on Antigen-Specific Immune Responses in HIV and Hepatitis C Virus Coinfection. <i>Journal of Infectious Diseases</i> , 2007, 195, 847-856.	4.0	16
113	Risk of Progression to Active Tuberculosis Among Foreign-Born Persons With Latent Tuberculosis. <i>Chest</i> , 2007, 131, 1811-1816.	0.8	20
114	Factors associated with loss to follow-up in a large tuberculosis treatment trial (TBTC Study 22). <i>Contemporary Clinical Trials</i> , 2007, 28, 288-294.	1.8	12
115	Predictors of failure to complete treatment for latent tuberculosis infection. <i>Journal of Infection</i> , 2007, 54, 262-266.	3.3	54
116	The Scope and Impact of Treatment of Latent Tuberculosis Infection in the United States and Canada. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 174, 481-481.	5.6	0
117	The Scope and Impact of Treatment of Latent Tuberculosis Infection in the United States and Canada. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 927-931.	5.6	103
118	Predicting Non-Completion of Treatment for Latent Tuberculosis Infection. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 174, 717-721.	5.6	103
119	Lack of Weight Gain and Relapse Risk in a Large Tuberculosis Treatment Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 174, 344-348.	5.6	144
120	Endothelial Function in HIV-Infected Persons. <i>Clinical Infectious Diseases</i> , 2006, 42, 1325-1332.	5.8	191
121	Environmental Risk Factors for Infection with <i>Mycobacterium avium</i> Complex. <i>American Journal of Epidemiology</i> , 2006, 164, 32-40.	3.4	92
122	High Rates of Clinical and Subclinical Tuberculosis among HIV-Infected Ambulatory Subjects in Tanzania. <i>Clinical Infectious Diseases</i> , 2005, 40, 1500-1507.	5.8	176
123	HIV Infection Does Not Affect the Performance of Noninvasive Markers of Fibrosis for the Diagnosis of Hepatitis C Virus-Related Liver Disease. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2005, 40, 538-544.	2.1	100
124	Hospital Water as a Source of <i>Mycobacterium avium</i> Complex Isolates in Respiratory Specimens. <i>Journal of Infectious Diseases</i> , 2004, 189, 98-104.	4.0	73
125	Health-Related Quality of Life of Patients with HIV Disease: Impact of Hepatitis C Coinfection. <i>Clinical Infectious Diseases</i> , 2004, 38, 572-578.	5.8	73
126	Human Immunodeficiency Virus Infection in a Rural Community in the United States. <i>American Journal of Epidemiology</i> , 2004, 160, 582-588.	3.4	24



#	ARTICLE	IF	CITATIONS
127	Priorities for the Treatment of Latent Tuberculosis Infection in the United States. New England Journal of Medicine, 2004, 350, 2060-2067.	27.0	581
128	Integration of a participatory research strategy into a rural health survey. Journal of General Internal Medicine, 2003, 18, 586-588.	2.6	19
129	Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet, The, 2002, 360, 528-534.	13.7	378
130	Pilot study of treatment of Buruli ulcer with rifampin and dapsone. International Journal of Infectious Diseases, 2002, 6, 60-65.	3.3	44
131	Disseminated Mycobacterium avium Complex Disease among Patients Infected with Human Immunodeficiency Virus, 1985-2000. Clinical Infectious Diseases, 2001, 33, 1938-1943.	5.8	71
132	A Large, Simple Trial of a Tuberculosis Vaccine. Clinical Infectious Diseases, 2000, 30, S213-S216.	5.8	9
133	Practice Guidelines for the Treatment of Tuberculosis. Clinical Infectious Diseases, 2000, 31, 633-639.	5.8	130
134	Risk of Cryptosporidium parvum Transmission between Hospital Roommates. Clinical Infectious Diseases, 2000, 31, 947-950.	5.8	31
135	The Global Problem of Multidrug-Resistant Tuberculosis. JAMA - Journal of the American Medical Association, 2000, 283, 2575.	7.4	32
136	Geographic and Seasonal Variation in Mycobacterium avium Bacteremia Among North American Patients With AIDS. American Journal of the Medical Sciences, 1997, 313, 341-345.	1.1	13
137	Treatment of 171 Patients with Pulmonary Tuberculosis Resistant to Isoniazid and Rifampin. New England Journal of Medicine, 1993, 328, 527-532.	27.0	670
138	Mycobacterium avium Complex Infection in the Acquired Immunodeficiency Syndrome. New England Journal of Medicine, 1991, 324, 1332-1338.	27.0	1,006
139	Effect of treatment adherence on the association between sex and unfavourable treatment outcomes among tuberculosis patients in Puducherry, India: a mediation analysis. Journal of Public Health, 0, , .	1.8	0